Search hospitals

>

Georgia

>

Atlanta

Emory Saint Joseph's Hospital

Claim this profile

Atlanta, Georgia 30342

Global Leader in Breast Cancer

Global Leader in Lung Cancer

Conducts research for Breast cancer

Conducts research for Pancreatic Cancer

Conducts research for Cancer

320 reported clinical trials

58 medical researchers

Photo of Emory Saint Joseph's Hospital in AtlantaPhoto of Emory Saint Joseph's Hospital in AtlantaPhoto of Emory Saint Joseph's Hospital in Atlanta

Summary

Emory Saint Joseph's Hospital is a medical facility located in Atlanta, Georgia. This center is recognized for care of Breast Cancer, Lung Cancer, Breast cancer, Pancreatic Cancer, Cancer and other specialties. Emory Saint Joseph's Hospital is involved with conducting 320 clinical trials across 466 conditions. There are 58 research doctors associated with this hospital, such as Ticiana A. Leal, Conor Steuer, Olatunji Alese, and Mehmet Bilen, MD.

Area of expertise

1

Breast Cancer

Global Leader

Emory Saint Joseph's Hospital has run 63 trials for Breast Cancer. Some of their research focus areas include:

ER positive
Stage IV
HER2 negative
2

Lung Cancer

Global Leader

Emory Saint Joseph's Hospital has run 51 trials for Lung Cancer. Some of their research focus areas include:

Stage IV
Stage II
Stage III

Top PIs

Clinical Trials running at Emory Saint Joseph's Hospital

Breast Cancer

Lung Cancer

Breast cancer

Prostate Cancer

Brain Tumor

Esophageal cancer

Ovarian Cancer

Liver Cancer

Uterine Cancer

Pancreatic Cancer

Image of trial facility.

Carvedilol

for Preventing Heart Problems in HER2 Positive Breast Cancer

This trial has two cohorts of patients with human epidermal growth factor receptor (HER)-2-positive breast cancer that has spread to other places in the body. All patients must be receiving trastuzumab-based treatment. Both cohorts are being observed for cardiac toxicity. The largest cohort (currently open to accrual) is observational, and contains patients who are taking a beta blocker, ACE inhibitor, or ARB as well as their trastuzumab-based treatment. The goal is to understand how common cardiac problems are in this group of patients at high risk. The smaller cohort (currently closed to accrual) is randomized. Patients in this second cohort are randomized to either carvedilol or no treatment, with the goal of seeing whether carvedilol (used to treat heart failure and high blood pressure) may prevent the heart from side effects of chemotherapy.

Recruiting

2 awards

Phase 3

23 criteria

Image of trial facility.

Durvalumab + Chemotherapy

for Breast Cancer

This phase III trial compares the addition of an immunotherapy drug (durvalumab) to usual chemotherapy versus usual chemotherapy alone in treating patients with MammaPrint High 2 Risk (MP2) stage II-III hormone receptor positive, HER2 negative breast cancer. Immunotherapy with monoclonal antibodies, such as durvalumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs, such as paclitaxel, doxorubicin, and cyclophosphamide work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. There is some evidence from previous clinical trials that people who have a MammaPrint High 2 Risk result may be more likely to respond to chemotherapy and immunotherapy. Adding durvalumab to usual chemotherapy may be able to prevent the cancer from returning for patients with MP2 stage II-III hormone receptor positive, HER2 negative breast cancer.

Recruiting

2 awards

Phase 3

40 criteria

Image of trial facility.

Mindfulness Approaches

for Living After Breast Cancer

NRG-CC015 is a prospective, randomized phase III clinical trial to evaluate the efficacy of two distinct digital approaches for delivering a mindfulness-based intervention: a live, instructor-led version delivered over Zoom (MAPs LO), and an app-based, self-paced version (MAPs App). Participants will include younger breast cancer survivors (BCS) who were diagnosed with breast cancer at or before age 50 years, have completed their primary cancer treatment (i.e., surgery, radiation, and/or chemotherapy) at least 6 months earlier, and report elevated depressive symptoms.

Recruiting

2 awards

Phase 3

5 criteria

Similar Hospitals nearby

Frequently asked questions

What kind of research happens at Emory Saint Joseph's Hospital?

Where is Emory Saint Joseph's Hospital located?

Who should I call to ask about financial aid or insurance network?

What insurance does Emory Saint Joseph's Hospital accept?

What awards or recognition has Emory Saint Joseph's Hospital received?